Aptivus is a drug owned by Boehringer Ingelheim Pharmaceuticals Inc. It is protected by 8 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 29, 2020. Details of Aptivus's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US6147095 (Pediatric) | Method for improving the pharmacokinetics of tipranavir |
Apr, 2020
(4 years ago) |
Expired
|
|
US5852195 (Pediatric) | Pyranone compounds useful to treat retroviral infections |
Dec, 2019
(4 years ago) |
Expired
|
| US6147095 | Method for improving the pharmacokinetics of tipranavir |
Oct, 2019
(5 years ago) |
Expired
|
| US5852195 | Pyranone compounds useful to treat retroviral infections |
Jun, 2019
(5 years ago) |
Expired
|
|
US6231887 (Pediatric) | Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation |
Jan, 2019
(5 years ago) |
Expired
|
| US6231887 | Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation |
Jul, 2018
(6 years ago) |
Expired
|
|
US6169181 (Pediatric) | Compounds useful to treat retroviral infections |
Nov, 2014
(10 years ago) |
Expired
|
| US6169181 | Compounds useful to treat retroviral infections |
May, 2014
(10 years ago) |
Expired
|
FDA has granted several exclusivities to Aptivus. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Aptivus, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Aptivus.
Exclusivity Information
Aptivus holds 1 exclusivities. All of its exclusivities have expired in 2011. Details of Aptivus's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Dec 23, 2011 |
US patents provide insights into the exclusivity only within the United States, but Aptivus is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Aptivus's family patents as well as insights into ongoing legal events on those patents.
Aptivus's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Aptivus's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Apr 29, 2020 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Aptivus Generics:
There are no approved generic versions for Aptivus as of now.
About Aptivus
Aptivus is a drug owned by Boehringer Ingelheim Pharmaceuticals Inc. It is used for treating HIV-1 infection by co-administering tipranavir and ritonavir. Aptivus uses Tipranavir as an active ingredient. Aptivus was launched by Boehringer Ingelheim in 2008.
Approval Date:
Aptivus was approved by FDA for market use on 23 June, 2008.
Active Ingredient:
Aptivus uses Tipranavir as the active ingredient. Check out other Drugs and Companies using Tipranavir ingredient
Treatment:
Aptivus is used for treating HIV-1 infection by co-administering tipranavir and ritonavir.
Dosage:
Aptivus is available in the following dosage forms - solution form for oral use, capsule form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 100MG/ML | SOLUTION | Discontinued | ORAL |
| 250MG | CAPSULE | Prescription | ORAL |